ClinicalTrials.gg
CompletedNCT05989048Updated May 22, 2026Results posted

A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

A Phase 3 interventional study of Zavegepant and Placebo in Migraine, sponsored by Pfizer. Completed at 61 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,414
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing zavegepant in Migraine Disorders — 4 open to participants now, 4 under way, none of them phase 3. zavegepant · Migraine Disorders.

Enrollment
4th of 12
1,414 · median 225
Started
2023
with 1 other
Phase 3
3 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
8 of 12
Pfizer

Among the 12 studies testing zavegepant in Migraine Disorders, this one is the 4th largest by enrollment, is one of 2 that started in 2023, is one of 3 in phase 3, and was the 6th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

4 of the 12 studies testing zavegepant in Migraine Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About zavegepant

zavegepant: first FDA approval 2023 (ZAVZPRET). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing zavegepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to learn how safe and effective zavegepant is compared to placebo in the acute treatment of migraine in Asian adults. Migraine is a very painful headache with other associated symptoms such as nausea, photophobia and phonophobia. A placebo is a harmless treatment that has no medical effect.

This study is seeking for participants who:

  • have at least 1 year of migraine history before entering the study.
  • have 2 to 8 migraine headache attacks of moderate or severe intensity in each of the 3 months before entering the study.
  • have less than 15 days with headaches in each of the 3 months before entering the study. The headaches could be either due to migraine or not.

The participants in this study will receive zavegepant or placebo through intranasal route. Intranasal means medicine which is given through nose. Zavegepant or placebo will be taken if the participants have a migraine headache of moderate or severe intensity.

The study will compare the experiences of people receiving zavegepant to those of the people receiving placebo. This will help see if zavegepant is safe and effective in Asian adults.

Participants will be in this study for up to about 16 weeks. Participants will have 3 study visits at the study clinic and 1 through telephone contact.

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asian participants aged 18 years or older at screening.
  • Participants with minimum 1 year history of migraine (with or without aura) prior to the Screening Visit, consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:

    1. Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age.
    2. Migraine attacks, on average, lasting about 4-72 hours if untreated.
    3. Not more than 8 attacks of moderate or severe pain intensity per month within last 3 months.
    4. Participants must be able to distinguish migraine attacks from tension/cluster headaches.
    5. At least 2 consistent migraine headache attacks of moderate or severe intensity in each of the 3 months prior to the Screening Visit and throughout the Screening Phase (participant self-report).
    6. Less than 15 days with headaches (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and throughout the Screening Phase (participant self-report).
    7. Participants on prophylactic migraine medication are permitted to remain on therapy if they have been on a stable dose for at least 3 months prior to Screening Visit, and if the dose is not expected to change through the End of Treatment Visit.
    8. Participants with for use of triptans may be included provided they meet all other study entry criteria.

Exclusion criteria

Exclusion Criteria:

  • History of retinal migraine, basilar migraine or hemiplegic migraine.
  • History or current evidence of uncontrolled, unstable or recently diagnosed cardiovascular or cardiometabolic disease.
  • Major depressive disorder, anxiety disorder, or other significant psychiatric disorder.
  • Acute or chronic pain syndromes, psychiatric conditions, dementia, or significant neurological disorders (other than migraine) that interfere with study assessments.
  • Conditions that may affect the administration or absorption of the nasal product.
  • Medication overuse headaches.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,414 participants (actual)

Study arms

  • Experimental
    Zavegepant

    Zavegepant intranasal 10 mg

    Drug: Zavegepant

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • The participants will receive single active dose sufficient to treat 1 migraine headache of moderate or severe intensity within Treatment Phase.

  • DrugPlacebo

    Single dose of matching placebo taken within Treatment Phase.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Pain Freedom at 2 Hours Post-dose

    Pain freedom was defined as pain intensity being none at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).

    Time frame: At 2 hours post-dose

  2. Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose

    MBS was selected from nausea, phonophobia or photophobia before dosing by the participants. In this outcome measure, percentage of participants who recorded an MBS (present) before dosing and did not have the MBS (absent) at the time of evaluation (i.e., 2 hours post-dose) were reported.

    Time frame: At 2 hours post-dose

Secondary outcomes

  1. Percentage of Participants With Pain Relief at 15 Minutes Post-dose

    Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).

    Time frame: At 15 minutes post-dose

  2. Percentage of Participants With Pain Relief at 30 Minutes Post-dose

    Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).

    Time frame: At 30 minutes post-dose

  3. Percentage of Participants With Pain Relief at 2 Hours Post-dose

    Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).

    Time frame: At 2 hours post-dose

  4. Percentage of Participants Who Returned to Normal Function at 2 Hours Post-dose

    Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 2 hours post-dose) were reported.

    Time frame: At 2 hours post-dose

  5. Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose

    Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). This outcome of sustained pain relief was defined as pain intensity being mild or none at all time points from 2 to 24 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.

    Time frame: From 2 hours post-dose to 24 hours post-dose

  6. Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose

    Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). This outcome of sustained pain relief was defined as pain intensity being mild or none at all time points from 2 to 48 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.

    Time frame: From 2 hours post-dose to 48 hours post-dose

  7. Percentage of Participants Who Returned to Normal Function at 30 Minutes Post-dose

    Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 30 minutes post-dose) were reported.

    Time frame: At 30 minutes post-dose

  8. Percentage of Participants Who Returned to Normal Function at 60 Minutes Post-dose

    Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 60 minutes post-dose) were reported.

    Time frame: At 60 minutes post-dose

  9. Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose

    Freedom from phonophobia was defined as phonophobia absent at specified time point for participants with the phonophobia present at the time of dosing. In this outcome measure, percentage of participants who had phonophobia at the time of dosing and then recorded phonophobia absent at the time of evaluation (i.e., 2 hours post-dose) were reported.

    Time frame: At 2 hours post-dose

  10. Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose

    Freedom from photophobia was defined as photophobia absent at specified time point for participants with the photophobia present at the time of dosing. In this outcome measure, percentage of participants who had photophobia at the time of dosing and then recorded photophobia absent at the time of evaluation (i.e., 2 hours post-dose) were reported.

    Time frame: At 2 hours post-dose

  11. Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose

    Freedom from nausea was defined as nausea absent at specified time point for participants with the nausea present at the time of dosing. In this outcome measure, percentage of participants who had nausea at the time of dosing and then recorded nausea absent at time of evaluation (i.e., 2 hours post-dose) were reported.

    Time frame: At 2 hours post-dose

  12. Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose

    Pain freedom was defined as pain intensity being none at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). Sustained pain freedom was defined as pain intensity being none at all time points from 2 to 24 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.

    Time frame: From 2 hours post-dose to 24 hours post-dose

  13. Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose

    Pain freedom was defined as pain intensity being none at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). Sustained pain freedom was defined as pain intensity being none at all time points from 2 to 48 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.

    Time frame: From 2 hours post-dose to 48 hours post-dose

  14. Percentage of Participants With Pain Relapse at Any Time Point After 2 Hours Post-dose to 48 Hours Post-dose

    Pain relapse was defined as pain intensity of mild, moderate, or severe at any time point after 2 hours to 48 hours post-dose for participants with pain intensity of none at 2 hours post-dose. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).

    Time frame: From after 2 hours post-dose to 48 hours post-dose

  15. Percentage of Participants Taking Rescue Medication Within 24 Hours Post-dose

    Participants who did not experience relief (pain intensity of none or mild) of their migraine headache at the end of 2 hours post-dose, or the migraine was relieved at 2 hours post-dose, but then recurred to a moderate or severe pain intensity level, were permitted to use the following rescue medications: aspirin, ibuprofen, naproxen (or any other type of nonsteroidal anti-inflammatory drug), acetaminophen up to 1000 mg/day (this included Excedrin Migraine), antiemetics (for example, metoclopramide or promethazine), or baclofen.

    Time frame: Within 24 hours post-dose

  16. Percentage of Participants With Pain Relief at 60 Minutes Post-dose

    Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).

    Time frame: At 60 minutes post-dose

  17. Percentage of Participants Who Returned to Normal Function at 15 Minutes Post-dose

    Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 15 minutes post-dose) were reported.

    Time frame: At 15 minutes post-dose

  18. Number of Participants With Adverse Events (AEs) of Moderate or Severe Intensity: On-Treatment Period

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Moderate AE: A type of AE that was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activity/activities of daily living (ADL), causing discomfort, but posed no significant or permanent risk of harm to the research participant. Severe AE: A type of AE that interrupted usual ADL, or significantly affected clinical status, or might have required intensive therapeutic intervention.

    Time frame: On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days

  19. Number of Participants With AEs of Moderate or Severe Intensity: Follow-up Period

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Moderate AE: A type of AE that was usually alleviated with additional specific therapeutic intervention. The event interfered with usual ADL, causing discomfort, but posed no significant or permanent risk of harm to the research participant. Severe AE: A type of AE that interrupted usual ADL, or significantly affected clinical status, or might have required intensive therapeutic intervention.

    Time frame: Follow-up period: Follow-up period was after the EOT visit and through the follow-up visit, up to 33 days

  20. Number of Participants With Serious Adverse Events (SAEs): On-Treatment Period

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic, or other situations.

    Time frame: On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days

  21. Number of Participants With SAEs: Follow-up Period

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic, or other situations.

    Time frame: Follow-up period: Follow-up period was after the EOT visit and through the follow-up visit, up to 33 days

  22. Number of Participants With Local Irritation AEs: On-Treatment Period

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Local irritation AEs were associated with intranasal administration of study intervention (e.g., dysgeusia, nasal discomfort, oropharyngeal pain, throat irritation, and laryngeal discomfort).

    Time frame: On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days

  23. Number of Participants With Local Irritation AEs: Follow-up Period

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Local irritation AEs were associated with intranasal administration of study intervention (e.g., dysgeusia, nasal discomfort, oropharyngeal pain, throat irritation, and laryngeal discomfort).

    Time frame: Follow-up period: Follow-up period was after the EOT visit and through the follow-up visit, up to 33 days

  24. Number of Participants With Grade 3 to 4 Hematological Test Abnormalities: On-Treatment Period

    Hematological test abnormalities included: anemia, eosinophilia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophils count decreased, platelet count decreased and white blood cell decreased. Only those hematology test categories in which at least one participant in at least one reporting arm experienced a Grade 3 or Grade 4 abnormality were reported in this outcome measure. The hematological test abnormalities grade 3 to 4 were graded according to the common terminology criteria for adverse events (CTCAE) version (v) 5.0.

    Time frame: On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days

  25. Number of Participants With Grade 3 to 4 Clinical Chemistry Test Abnormalities: On-Treatment Period

    Clinical chemistry test abnormalities included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, blood lactate dehydrogenase increased, creatine phosphokinase (CPK) increased, chronic kidney disease, creatinine increased, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypocalcemia, hypoglycemia, hypokalemia and hyponatremia. Only those clinical chemistry test categories in which at least one participant in at least one reporting arm experienced a Grade 3 or Grade 4 abnormality were reported in this outcome measure. The clinical chemistry test abnormalities grade 3 to 4 were graded according to the CTCAE v 5.0.

    Time frame: On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days

07

Results

Posted May 22, 2026

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneZavegepantPlacebo
Started708706
Treated678675
Completed678673
Not completed3033
Withdrew: Withdrawal by subject01
Withdrew: Other01
Withdrew: Randomized but not treated3031
Follow-up Period
Participant flow — Follow-up Period
MilestoneZavegepantPlacebo
Started678675
Completed678673
Not completed02
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryPercentage of Participants With Pain Freedom at 2 Hours Post-dose

Pain freedom was defined as pain intensity being none at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).

Time frame:
At 2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Freedom at 2 Hours Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants With Pain Freedom at 2 Hours Post-dose23.2 (20.0 to 26.4)14.1 (11.4 to 16.7)
Statistical analysis
  • Zavegepant vs Placebo · Mantel Haenszel · p = <0.0001 · Difference in percentage: 9.2 · 95% CI 5.0 to 13.3The difference (Zavegepant-Placebo) was estimated based on Mantel-Haenszel risk estimation stratified by country/region. Corresponding confidence interval (CI) and p-value were calculated based on normal approximation.
PrimaryPercentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose

MBS was selected from nausea, phonophobia or photophobia before dosing by the participants. In this outcome measure, percentage of participants who recorded an MBS (present) before dosing and did not have the MBS (absent) at the time of evaluation (i.e., 2 hours post-dose) were reported.

Time frame:
At 2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose52.7 (49.0 to 56.5)39.9 (36.2 to 43.6)
Statistical analysis
  • Zavegepant vs Placebo · Mantel Haenszel · p = <0.0001 · Difference in percentage: 12.8 · 95% CI 7.5 to 18.1The difference (Zavegepant-Placebo) was estimated based on Mantel-Haenszel risk estimation stratified by country/region. Corresponding CI and p-value were calculated based on normal approximation.
SecondaryPercentage of Participants With Pain Relief at 15 Minutes Post-dose

Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).

Time frame:
At 15 minutes post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relief at 15 Minutes Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants With Pain Relief at 15 Minutes Post-dose14.5 (11.8 to 17.1)10.9 (8.5 to 13.3)
Statistical analysis
  • Zavegepant vs Placebo · Mantel Haenszel · p = =0.0480 · Difference in percentage: 3.6 · 95% CI 0.0 to 7.1The difference (Zavegepant-Placebo) was estimated based on Mantel-Haenszel risk estimation stratified by country/region. Corresponding CI and p-value were calculated based on normal approximation.
SecondaryPercentage of Participants With Pain Relief at 30 Minutes Post-dose

Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).

Time frame:
At 30 minutes post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relief at 30 Minutes Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants With Pain Relief at 30 Minutes Post-dose30.3 (26.8 to 33.7)24.1 (20.8 to 27.3)
Statistical analysis
  • Zavegepant vs Placebo · Mantel Haenszel · p = =0.0100 · Difference in percentage: 6.2 · 95% CI 1.5 to 10.9The difference (Zavegepant-Placebo) was estimated based on Mantel-Haenszel risk estimation stratified by country/region. Corresponding CI and p-value were calculated based on normal approximation.
SecondaryPercentage of Participants With Pain Relief at 2 Hours Post-dose

Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).

Time frame:
At 2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relief at 2 Hours Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants With Pain Relief at 2 Hours Post-dose67.2 (63.7 to 70.7)51.0 (47.2 to 54.8)
Statistical analysis
  • Zavegepant vs Placebo · Mantel Haenszel · p = <0.0001 · Difference in percentage: 16.2 · 95% CI 11.1 to 21.4The difference (Zavegepant-Placebo) was estimated based on Mantel-Haenszel risk estimation stratified by country/region. Corresponding CI and p-value were calculated based on normal approximation.
SecondaryPercentage of Participants Who Returned to Normal Function at 2 Hours Post-dose

Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 2 hours post-dose) were reported.

Time frame:
At 2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Returned to Normal Function at 2 Hours Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants Who Returned to Normal Function at 2 Hours Post-dose38.0 (34.2 to 41.9)24.4 (21.0 to 27.8)
Statistical analysis
  • Zavegepant vs Placebo · Mantel Haenszel · p = <0.0001 · Difference in percentage: 13.6 · 95% CI 8.5 to 18.7The difference (Zavegepant-Placebo) was estimated based on Mantel-Haenszel risk estimation stratified by country/region. Corresponding CI and p-value were calculated based on normal approximation.
SecondaryPercentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose

Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). This outcome of sustained pain relief was defined as pain intensity being mild or none at all time points from 2 to 24 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.

Time frame:
From 2 hours post-dose to 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose55.8 (52.1 to 59.6)39.8 (36.1 to 43.5)
Statistical analysis
  • Zavegepant vs Placebo · Mantel Haenszel · p = <0.0001 · Difference in percentage: 16.1 · 95% CI 10.9 to 21.4The difference (Zavegepant-Placebo) was estimated based on Mantel-Haenszel risk estimation stratified by country/region. Corresponding CI and p-value were calculated based on normal approximation.
SecondaryPercentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose

Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). This outcome of sustained pain relief was defined as pain intensity being mild or none at all time points from 2 to 48 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.

Time frame:
From 2 hours post-dose to 48 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose53.3 (49.6 to 57.1)38.6 (34.9 to 42.3)
Statistical analysis
  • Zavegepant vs Placebo · Mantel Haenszel · p = <0.0001 · Difference in percentage: 14.8 · 95% CI 9.6 to 20.0The difference (Zavegepant-Placebo) was estimated based on Mantel-Haenszel risk estimation stratified by country/region. Corresponding CI and p-value were calculated based on normal approximation.
SecondaryPercentage of Participants Who Returned to Normal Function at 30 Minutes Post-dose

Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 30 minutes post-dose) were reported.

Time frame:
At 30 minutes post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Returned to Normal Function at 30 Minutes Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants Who Returned to Normal Function at 30 Minutes Post-dose8.3 (6.1 to 10.5)6.3 (4.4 to 8.2)
Statistical analysis
  • Zavegepant vs Placebo · Mantel Haenszel · p = =0.1677 · Difference in percentage: 2 · 95% CI -0.9 to 4.9The difference (Zavegepant-Placebo) was estimated based on Mantel-Haenszel risk estimation stratified by country/region. Corresponding CI and p-value were calculated based on normal approximation.
SecondaryPercentage of Participants Who Returned to Normal Function at 60 Minutes Post-dose

Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 60 minutes post-dose) were reported.

Time frame:
At 60 minutes post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Returned to Normal Function at 60 Minutes Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants Who Returned to Normal Function at 60 Minutes Post-dose22.3 (19.0 to 25.6)14.6 (11.8 to 17.4)
Statistical analysis
  • Zavegepant vs Placebo · Mantel Haenszel · p = =0.0005 · Difference in percentage: 7.7 · 95% CI 3.4 to 12.0The difference (Zavegepant-Placebo) was estimated based on Mantel-Haenszel risk estimation stratified by country/region. Corresponding CI and p-value were calculated based on normal approximation.
SecondaryPercentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose

Freedom from phonophobia was defined as phonophobia absent at specified time point for participants with the phonophobia present at the time of dosing. In this outcome measure, percentage of participants who had phonophobia at the time of dosing and then recorded phonophobia absent at the time of evaluation (i.e., 2 hours post-dose) were reported.

Time frame:
At 2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose52.1 (47.4 to 56.9)36.3 (31.8 to 40.9)
SecondaryPercentage of Participants With Freedom From Photophobia at 2 Hours Post-dose

Freedom from photophobia was defined as photophobia absent at specified time point for participants with the photophobia present at the time of dosing. In this outcome measure, percentage of participants who had photophobia at the time of dosing and then recorded photophobia absent at the time of evaluation (i.e., 2 hours post-dose) were reported.

Time frame:
At 2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose49.1 (44.5 to 53.7)38.0 (33.4 to 42.5)
SecondaryPercentage of Participants With Freedom From Nausea at 2 Hours Post-dose

Freedom from nausea was defined as nausea absent at specified time point for participants with the nausea present at the time of dosing. In this outcome measure, percentage of participants who had nausea at the time of dosing and then recorded nausea absent at time of evaluation (i.e., 2 hours post-dose) were reported.

Time frame:
At 2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose64.2 (59.9 to 68.6)51.3 (46.8 to 55.8)
SecondaryPercentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose

Pain freedom was defined as pain intensity being none at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). Sustained pain freedom was defined as pain intensity being none at all time points from 2 to 24 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.

Time frame:
From 2 hours post-dose to 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose17.7 (14.8 to 20.6)11.2 (8.8 to 13.6)
SecondaryPercentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose

Pain freedom was defined as pain intensity being none at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). Sustained pain freedom was defined as pain intensity being none at all time points from 2 to 48 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.

Time frame:
From 2 hours post-dose to 48 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose17.3 (14.4 to 20.1)11.1 (8.7 to 13.4)
SecondaryPercentage of Participants With Pain Relapse at Any Time Point After 2 Hours Post-dose to 48 Hours Post-dose

Pain relapse was defined as pain intensity of mild, moderate, or severe at any time point after 2 hours to 48 hours post-dose for participants with pain intensity of none at 2 hours post-dose. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).

Time frame:
From after 2 hours post-dose to 48 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relapse at Any Time Point After 2 Hours Post-dose to 48 Hours Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants With Pain Relapse at Any Time Point After 2 Hours Post-dose to 48 Hours Post-dose29.3 (22.2 to 36.4)22.3 (13.9 to 30.8)
SecondaryPercentage of Participants Taking Rescue Medication Within 24 Hours Post-dose

Participants who did not experience relief (pain intensity of none or mild) of their migraine headache at the end of 2 hours post-dose, or the migraine was relieved at 2 hours post-dose, but then recurred to a moderate or severe pain intensity level, were permitted to use the following rescue medications: aspirin, ibuprofen, naproxen (or any other type of nonsteroidal anti-inflammatory drug), acetaminophen up to 1000 mg/day (this included Excedrin Migraine), antiemetics (for example, metoclopramide or promethazine), or baclofen.

Time frame:
Within 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Taking Rescue Medication Within 24 Hours Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants Taking Rescue Medication Within 24 Hours Post-dose17.1 (14.3 to 20.0)24.4 (21.1 to 27.6)
SecondaryPercentage of Participants With Pain Relief at 60 Minutes Post-dose

Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).

Time frame:
At 60 minutes post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relief at 60 Minutes Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants With Pain Relief at 60 Minutes Post-dose48.6 (44.8 to 52.4)41.9 (38.1 to 45.6)
SecondaryPercentage of Participants Who Returned to Normal Function at 15 Minutes Post-dose

Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 15 minutes post-dose) were reported.

Time frame:
At 15 minutes post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Returned to Normal Function at 15 Minutes Post-dose
Percentage of participantsZavegepantPlacebo
Percentage of Participants Who Returned to Normal Function at 15 Minutes Post-dose4.1 (2.5 to 5.6)2.7 (1.4 to 4.0)
SecondaryNumber of Participants With Adverse Events (AEs) of Moderate or Severe Intensity: On-Treatment Period

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Moderate AE: A type of AE that was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activity/activities of daily living (ADL), causing discomfort, but posed no significant or permanent risk of harm to the research participant. Severe AE: A type of AE that interrupted usual ADL, or significantly affected clinical status, or might have required intensive therapeutic intervention.

Time frame:
On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) of Moderate or Severe Intensity: On-Treatment Period
ParticipantsZavegepant: On-Treatment PeriodPlacebo: On-Treatment Period
Number of Participants With Adverse Events (AEs) of Moderate or Severe Intensity: On-Treatment Period96
SecondaryNumber of Participants With AEs of Moderate or Severe Intensity: Follow-up Period

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Moderate AE: A type of AE that was usually alleviated with additional specific therapeutic intervention. The event interfered with usual ADL, causing discomfort, but posed no significant or permanent risk of harm to the research participant. Severe AE: A type of AE that interrupted usual ADL, or significantly affected clinical status, or might have required intensive therapeutic intervention.

Time frame:
Follow-up period: Follow-up period was after the EOT visit and through the follow-up visit, up to 33 days
Reported as:
Count of participants · Participants
Number of Participants With AEs of Moderate or Severe Intensity: Follow-up Period
ParticipantsZavegepant: Follow-up PeriodPlacebo: Follow-up Period
Number of Participants With AEs of Moderate or Severe Intensity: Follow-up Period83
SecondaryNumber of Participants With Serious Adverse Events (SAEs): On-Treatment Period

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic, or other situations.

Time frame:
On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs): On-Treatment Period
ParticipantsZavegepant: On-Treatment PeriodPlacebo: On-Treatment Period
Number of Participants With Serious Adverse Events (SAEs): On-Treatment Period21
SecondaryNumber of Participants With SAEs: Follow-up Period

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic, or other situations.

Time frame:
Follow-up period: Follow-up period was after the EOT visit and through the follow-up visit, up to 33 days
Reported as:
Count of participants · Participants
Number of Participants With SAEs: Follow-up Period
ParticipantsZavegepant: Follow-up PeriodPlacebo: Follow-up Period
Number of Participants With SAEs: Follow-up Period30
SecondaryNumber of Participants With Local Irritation AEs: On-Treatment Period

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Local irritation AEs were associated with intranasal administration of study intervention (e.g., dysgeusia, nasal discomfort, oropharyngeal pain, throat irritation, and laryngeal discomfort).

Time frame:
On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days
Reported as:
Count of participants · Participants
Number of Participants With Local Irritation AEs: On-Treatment Period
ParticipantsZavegepant: On-Treatment PeriodPlacebo: On-Treatment Period
Number of Participants With Local Irritation AEs: On-Treatment Period416
SecondaryNumber of Participants With Local Irritation AEs: Follow-up Period

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Local irritation AEs were associated with intranasal administration of study intervention (e.g., dysgeusia, nasal discomfort, oropharyngeal pain, throat irritation, and laryngeal discomfort).

Time frame:
Follow-up period: Follow-up period was after the EOT visit and through the follow-up visit, up to 33 days
Reported as:
Count of participants · Participants
Number of Participants With Local Irritation AEs: Follow-up Period
ParticipantsZavegepant: Follow-up PeriodPlacebo: Follow-up Period
Number of Participants With Local Irritation AEs: Follow-up Period00
SecondaryNumber of Participants With Grade 3 to 4 Hematological Test Abnormalities: On-Treatment Period

Hematological test abnormalities included: anemia, eosinophilia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophils count decreased, platelet count decreased and white blood cell decreased. Only those hematology test categories in which at least one participant in at least one reporting arm experienced a Grade 3 or Grade 4 abnormality were reported in this outcome measure. The hematological test abnormalities grade 3 to 4 were graded according to the common terminology criteria for adverse events (CTCAE) version (v) 5.0.

Time frame:
On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Hematological Test Abnormalities: On-Treatment Period
ParticipantsZavegepant: On-Treatment PeriodPlacebo: On-Treatment Period
Anemia10
Lymphocyte count decreased10
Neutrophil count decreased22
SecondaryNumber of Participants With Grade 3 to 4 Clinical Chemistry Test Abnormalities: On-Treatment Period

Clinical chemistry test abnormalities included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, blood lactate dehydrogenase increased, creatine phosphokinase (CPK) increased, chronic kidney disease, creatinine increased, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypocalcemia, hypoglycemia, hypokalemia and hyponatremia. Only those clinical chemistry test categories in which at least one participant in at least one reporting arm experienced a Grade 3 or Grade 4 abnormality were reported in this outcome measure. The clinical chemistry test abnormalities grade 3 to 4 were graded according to the CTCAE v 5.0.

Time frame:
On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Clinical Chemistry Test Abnormalities: On-Treatment Period
ParticipantsZavegepant: On-Treatment PeriodPlacebo: On-Treatment Period
CPK increased44
Hyperglycemia10

Adverse events

Collected over On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days; Follow-up period: Follow-up period was after the EOT visit and through the follow-up visit, up to 33 days. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zavegepant: On-Treatment Period0/678 (0%)2/678 (0.3%)53/678 (7.8%)
Placebo: On-Treatment Period0/675 (0%)1/675 (0.1%)23/675 (3.4%)
Zavegepant: Follow-up Period0/678 (0%)3/678 (0.4%)0/678 (0%)
Placebo: Follow-up Period0/675 (0%)0/675 (0%)0/675 (0%)
Most frequent serious events
Most frequent serious events
EventZavegepant: On-Treatment PeriodPlacebo: On-Treatment PeriodZavegepant: Follow-up PeriodPlacebo: Follow-up Period
Coronary artery diseaseCardiac disorders0/6781/6750/6780/675
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/6780/6751/6780/675
Neck massMusculoskeletal and connective tissue disorders1/6780/6750/6780/675
Cerebral infarctionNervous system disorders0/6780/6751/6780/675
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/6780/6750/6780/675
EndometriosisReproductive system and breast disorders0/6780/6751/6780/675
Most frequent other events
Most frequent other events
EventZavegepant: On-Treatment PeriodPlacebo: On-Treatment PeriodZavegepant: Follow-up PeriodPlacebo: Follow-up Period
DysgeusiaNervous system disorders25/6782/6750/6780/675
Urinary tract infectionInfections and infestations14/67811/6750/6780/675
Nasal discomfortRespiratory, thoracic and mediastinal disorders12/6781/6750/6780/675
Upper respiratory tract infectionInfections and infestations9/6789/6750/6780/675

Baseline characteristics

Participants who were enrolled and took study intervention (Zavegepant or Placebo) were included in baseline analysis population.

Age, Continuous
Age, Continuous(Years)ZavegepantPlaceboTotal
Mean39.0 ± 9.9239.5 ± 10.4939.3 ± 10.21
Sex: Female, Male
Sex: Female, Male(Participants)ZavegepantPlaceboTotal
Female5355101045
Male143165308
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ZavegepantPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino6786751353
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ZavegepantPlaceboTotal
American Indian or Alaska Native000
Asian6786751353
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

61 sites
  • The Second People's hospital of Hefei
    Hefei, Anhui 230011, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality 100050, China
  • The First Medical Center of Chinese PLA General Hospital
    Beijing, Beijing Municipality 100853, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400016, China
  • Hainan General Hospital
    Haikou, Hainan 570311, China
  • Renmin Hospital Of Wuhan University
    Wuhan, Hebei 430060, China
  • The First Affiliated Hospital of Henan University of Science &Technology
    Luoyang, Henan 471000, China
  • The First Affiliated Hospital of Henan University of Science &Technology
    Luoyang, Henan 471003, China
  • People's Hospital of Zhengzhou
    Zhengzhou, Henan 450000, China
  • Wuhan Third Hospital
    Wuhan, Hubei 430074, China
  • Changsha Central Hospital
    Changsha, Hunan 410004, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
  • The Second People's Hospital of Lianyungang
    Lianyungang, Jiangsu 222006, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215004, China
  • Wuxi People's Hospital
    Wuxi, Jiangsu 214023, China
  • Affiliated Hospital of Jiangnan University
    Wuxi, Jiangsu 214125, China
  • The Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212008, China
  • Pingxiang People's Hospital
    Pingxiang, Jiangxi 337055, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130000, China
  • The People's Hospital of Liaoning Province
    Shenyang, Liaoning 110016, China
  • The First People's Hospital of Yinchuan
    Yinchuan, Ningxia 750001, China
  • General Hospital of Ningxia Medical Hospital
    Yinchuan, Ningxia 750003, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
  • Shaanxi Provincial People' Hospital
    Xi'an, Shaanxi 710068, China
  • Xian Gaoxin Hospital
    Xi'an, Shaanxi 710075, China
  • Xianyang Hospital of Yan'an University
    Xianyang, Shaanxi 716099, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Affiliated Hospital of Jining Medical University
    Jining, Shandong 272000, China
  • Liaocheng people's Hospital
    Liaocheng, Shandong 252000, China
  • Qingdao Central Hospital
    Qingdao, Shandong 266042, China
  • People's Hospital of Rizhao
    Rizhao, Shandong 276800, China
  • Huashan Hospital, Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • Shanghai East Hospital
    Shanghai, Shanghai Municipality 200123, China
  • Heping Hospital Affiliated to Changzhi Medical College
    Changzhi, Shanxi 046000, China
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Ruian People's Hospital
    Rui’an, Zhejiang 325200, China
  • The First Affiliated Hosptial of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
  • Peking University People's Hospital
    Beijing, 100044, China
  • Xuanwu Hospital Capital Medical University
    Beijing, 100053, China
  • Chongqing University Three Gorges Hospital
    Chongqing, 404000, China
  • The fourth people's hospital of chongqing
    Chongqing, China
  • Shanghai East Hospital
    Shanghai, 200120, China
  • Tianjin Union Medical Center
    Tianjin, 300000, China
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Inje University - Ilsan Paik Hospital
    Goyang-si, Kyǒnggi-do 10380, South Korea
  • Hallym University Dongtan Sacred Heart Hospital
    Hwaseong-si, Kyǒnggi-do 18450, South Korea
  • Seoul National University Bundang Hospital
    Seongnam, Kyǒnggi-do 13620, South Korea
  • The Catholic University of Korea, Uijeongbu St. Mary's Hospital
    Uijeongbu-si, Kyǒnggi-do 11765, South Korea
  • Dong-A University Hospital
    Busan, Pusan-kwangyǒkshi 49201, South Korea
  • Nowon Eulji Medical Center, Eulji University
    Seoul, Seoul-teukbyeolsi [seoul] 01830, South Korea
  • Seoul National University Hospital
    Seoul, Seoul-teukbyeolsi [seoul] 03080, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, Seoul-teukbyeolsi [seoul] 03722, South Korea
  • Asan Medical Center
    Seoul, Seoul-teukbyeolsi [seoul] 05505, South Korea
  • Ewha Womans University Seoul Hospital
    Seoul, Seoul-teukbyeolsi [seoul] 07804, South Korea
  • Kangbuk Samsung Hospital
    Seoul, 03181, South Korea
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Tri-Service General Hospital
    Taipei, 11490, Taiwan
  • Chang Gung Medical Foundation-Linkou Branch
    Taoyuan, 333, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in May 2025, 18 months.

Results were first posted in May 2026, 11 months after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 18 months is close to that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2023
First posted
Aug 14, 2023
StartActual
Nov 29, 2023
Primary completionActual
May 30, 2025
CompletionActual
May 30, 2025
Results first posted
May 22, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05989048
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Nov 29, 2023
Primary completion
May 30, 2025
Completion
May 30, 2025
Results posted
May 22, 2026
Last update
May 22, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zavegepant

Start the discussion